NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Sclerosis


Return to Library

Free Sclerosis Articles


Study data from B. Benedetti et al provide new insights into multiple sclerosis



2009 AUG 3 - (NewsRx.com) -- "The term benign multiple sclerosis (BMS) is referred to patients who have a mild or absent disability several years after disease clinical onset. Axonal damage can be measured in vivo using proton MR spectroscopy (H-1-MRS)," scientists in Milan, Italy report.

"In this study, we quantified the severity of ''global'' axonal damage in BMS and early relapsing-remitting (RR) MS patients, using whole brain N-acetylaspartate (WBNAA) H-1-MRS, to better elucidate the structural correlates of a non-disabling disease evolution. WBNAA concentration was measured in 37 patients with BMS (mean disease duration 22.3 years) and 17 patients with early RRMS (mean disease duration 4.0 years), using an unlocalized H-1-MRS sequence. Dual echo and T1-weighted scans were also obtained to measure T2-hyperintense lesion volume (TLV) and normalized brain volume (NBV). TLV was higher in BMS (mean TLV = 13.1 mL) than in early RRMS patients (mean TLV = 7.2 mL) (P = 0.018), whereas neither NBV (mean NBV: 1491.0 mL in BMS vs 1520.3 mL in RRMS) nor WBNAA concentration (mean WBNAA: 10.5 mmol in BMS vs 11.4 mmol in RRMS) significantly differed between the two groups. In MS patients, no correlation was found between WBNAA concentration and Expanded Disability Status Scale (EDSS), TLV and NBV. The similar WBNAA concentrations seen in BMS and early RRMS patients fit with the notion that a non-disabling long-term evolution of MS may be due, at least in part, to non-progression of pathology. Such a condition seems to be independent from MRI-visible lesions burden," wrote B. Benedetti and colleagues.

The researchers concluded: "Multiple Sclerosis 2009; 15: 789-794. http://msj.sagepub.com."

Benedetti and colleagues published their study in Multiple Sclerosis (In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis. Multiple Sclerosis, 2009;15(7):789-794).

For additional information, contact M. Filippi, San Raffaele Science Institute & University, Neuroimaging Research Unit, Dept. of Neurology, Via Olgettina 60, I-20132 Milan, Italy.

The publisher's contact information for the journal Multiple Sclerosis is: Sage Publications Ltd., 1 Olivers Yard, 55 City Road, London EC1Y 1SP, England.

Keywords: Italy, Milan, Multiple Sclerosis, Neuroimmunology, Neurology, Spectroscopy, Surgery.

This article was prepared by Pain & Central Nervous System Week editors from staff and other reports. Copyright 2009, Pain & Central Nervous System Week via NewsRx.com.

NewsRx NewsRx NewsRx
-----------------------
PR Login